![Mary Tagliaferri](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mary Tagliaferri
Directeur Technique/Scientifique/R&D chez
NEKTAR THERAPEUTICS
Profil
Dr. Mary A. Tagliaferri, MD, is an Independent Director at Iambic Therapeutics, Inc. and a Chief Medical Officer at Nektar Therapeutics.
She is on the Board of Directors at ADARx Pharmaceuticals, Inc. and Iambic Therapeutics, Inc. Dr. Tagliaferri was previously employed as an Independent Director by Y-mAbs Therapeutics, Inc., an Independent Director by Rayzebio, Inc., an Independent Director by Enzo Biochem, Inc., a Chief Medical Officer by Kanglaite USA, Inc., a President, Secretary, Treasurer & Director by Bionovo, Inc., and a Secretary, Treasurer & Chief Regulatory Officer by Lighten Up Enterprises International, Inc. She also served on the board at Atossa Therapeutics, Inc. She received her undergraduate degree from Cornell University, a graduate degree from American College of Traditional Chinese Medicine and a doctorate degree from The University of California, San Francisco.
Postes actifs de Mary Tagliaferri
| Sociétés | Poste | Début |
|---|---|---|
| NEKTAR THERAPEUTICS | Directeur Technique/Scientifique/R&D | 01/09/2025 |
| ADARX PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/11/2025 |
Entos, Inc.
 Entos, Inc. Packaged SoftwareTechnology Services Develops AI driven platform for drug discovery | Directeur/Membre du Conseil | 01/08/2024 |
Anciens postes connus de Mary Tagliaferri
| Sociétés | Poste | Fin |
|---|---|---|
| YMAS THER | Directeur/Membre du Conseil | 11/07/2025 |
| ENZO BIOCHEM, INC. | Président | 25/10/2023 |
| RAYZEBIO, INC. | Directeur/Membre du Conseil | 26/02/2024 |
Kanglaite USA, Inc.
 Kanglaite USA, Inc. Pharmaceuticals: MajorHealth Technology The private company is based in Redwood City, CA. Kanglaite USA, Inc. is a biotechnology company developing treatments for solid tumors and cancer-associated anorexia-cachexia syndrome. The company’s lead product, Kanglaite Injection (KLTi), has been approved in China for the treatment of advanced non-small cell lung cancer and hepatocellular cancer, and is currently under investigation in the United States for cancer-related indications. The company focuses on discovering and developing natural therapies for various cancers, including pancreatic and prostate cancer. | Directeur Technique/Scientifique/R&D | 01/06/2014 |
| BIONOVO INC. | Fondateur | 01/06/2012 |
Formation de Mary Tagliaferri
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
91
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Enzo Biochem, Inc.
 Enzo Biochem, Inc. BiotechnologyHealth Technology Provides enabling life science technologies for research, drug discovery, drug development and diagnostic solutions | Health Technology |
Nektar Therapeutics
 Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
Lighten Up Enterprises International, Inc.
 Lighten Up Enterprises International, Inc. Financial ConglomeratesFinance Development stage company | Finance |
Bionovo, Inc.
 Bionovo, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals & drugs | Health Technology |
Atossa Therapeutics, Inc.
 Atossa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics and delivery methods for the treatment of breast cancer & other breast conditions | Health Technology |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
American College of Traditional Chinese Medicine
 American College of Traditional Chinese Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Y-mAbs Therapeutics, Inc.
 Y-mAbs Therapeutics, Inc. BiotechnologyHealth Technology Develops radioimmunotherapy and antibody-based oncology therapies for treating cancer | Health Technology |
Kanglaite USA, Inc.
Kanglaite USA, Inc. Pharmaceuticals: MajorHealth Technology The private company is based in Redwood City, CA. Kanglaite USA, Inc. is a biotechnology company developing treatments for solid tumors and cancer-associated anorexia-cachexia syndrome. The company’s lead product, Kanglaite Injection (KLTi), has been approved in China for the treatment of advanced non-small cell lung cancer and hepatocellular cancer, and is currently under investigation in the United States for cancer-related indications. The company focuses on discovering and developing natural therapies for various cancers, including pancreatic and prostate cancer. | Health Technology |
ADARx Pharmaceuticals, Inc.
 ADARx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage pipeline that develops RNA medicines for diseases | Commercial Services |
Rayzebio, Inc.
 Rayzebio, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapeutics for cancer treatment | Health Technology |
Entos, Inc.
Entos, Inc. Packaged SoftwareTechnology Services Develops AI driven platform for drug discovery | Technology Services |
